PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma.
Amino acid metabolism
Immunoglobulins
Immunology
Lymphomas
Metabolism
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
02 05 2022
02 05 2022
Historique:
received:
26
07
2021
accepted:
16
03
2022
pubmed:
23
3
2022
medline:
4
5
2022
entrez:
22
3
2022
Statut:
ppublish
Résumé
The synthesis of serine from glucose is a key metabolic pathway supporting cellular proliferation in healthy and malignant cells. Despite this, the role that this aspect of metabolism plays in germinal center biology and pathology is not known. Here, we performed a comprehensive characterization of the role of the serine synthesis pathway in germinal center B cells and lymphomas derived from these cells. We demonstrate that upregulation of a functional serine synthesis pathway is a metabolic hallmark of B cell activation and the germinal center reaction. Inhibition of phosphoglycerate dehydrogenase (PHGDH), the first and rate-limiting enzyme in this pathway, led to defective germinal formation and impaired high-affinity antibody production. In addition, overexpression of enzymes involved in serine synthesis was a characteristic of germinal center B cell-derived lymphomas, with high levels of expression being predictive of reduced overall survival in diffuse large B cell lymphoma. Inhibition of PHGDH induced apoptosis in lymphoma cells, reducing disease progression. These findings establish PHGDH as a critical player in humoral immunity and a clinically relevant target in lymphoma.
Identifiants
pubmed: 35316216
pii: 153436
doi: 10.1172/JCI153436
pmc: PMC9057607
doi:
pii:
Substances chimiques
Serine
452VLY9402
Phosphoglycerate Dehydrogenase
EC 1.1.1.95
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : FC001057
Pays : United Kingdom
Organisme : Cancer Research UK
ID : FC001557
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C596/A26855
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 110020/Z/15/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 213555/Z/18/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : FC001557
Pays : United Kingdom
Organisme : Wellcome Trust
ID : FC001057
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J008060/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C355/A25137
Pays : United Kingdom
Organisme : Medical Research Council
ID : FC001557
Pays : United Kingdom
Organisme : Cancer Research UK
ID : FC001057
Pays : United Kingdom
Références
Nature. 2013 Jan 24;493(7433):542-6
pubmed: 23242140
Annu Rev Immunol. 2005;23:487-513
pubmed: 15771579
Pigment Cell Melanoma Res. 2011 Dec;24(6):1112-5
pubmed: 21981974
ACS Chem Biol. 2015 Feb 20;10(2):510-6
pubmed: 25406093
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Cancer Res. 1993 Apr 1;53(7):1665-9
pubmed: 8453639
Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13180-5
pubmed: 10557294
Curr Biol. 1999 Nov 4;9(21):1255-8
pubmed: 10556095
Blood. 2008 Jan 15;111(2):750-60
pubmed: 17942753
Blood. 2006 Jun 1;107(11):4458-65
pubmed: 16449529
Exp Cell Res. 1978 Oct 1;116(1):127-37
pubmed: 699986
Cell Metab. 2019 Jun 4;29(6):1410-1421.e4
pubmed: 30905671
Blood. 2011 Oct 27;118(17):4635-45
pubmed: 21878673
J Cell Biol. 2016 Aug 1;214(3):249-57
pubmed: 27458133
Nat Rev Immunol. 2009 Jan;9(1):15-27
pubmed: 19079135
Am J Physiol Endocrinol Metab. 2004 Feb;286(2):E272-9
pubmed: 14559726
Blood. 2012 Jan 5;119(1):170-9
pubmed: 22086413
Nature. 2007 Feb 8;445(7128):661-5
pubmed: 17251932
Immunol Today. 2000 Apr;21(4):192-9
pubmed: 10740243
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7
pubmed: 6961453
Nat Commun. 2021 Jan 14;12(1):366
pubmed: 33446657
Cell. 2017 Feb 9;168(4):657-669
pubmed: 28187287
Cancer Lett. 2020 Apr 28;476:97-105
pubmed: 32032680
Nature. 1996 Jun 27;381(6585):751-8
pubmed: 8657279
Cancers (Basel). 2020 Mar 03;12(3):
pubmed: 32138178
Arch Biochem Biophys. 1985 Jan;236(1):277-88
pubmed: 2578270
J Immunol. 2007 Oct 15;179(8):4953-7
pubmed: 17911579
Breast Cancer Res Treat. 2011 Jan;125(2):421-30
pubmed: 20352489
Cell. 2018 Jul 26;174(3):716-729.e27
pubmed: 29961576
N Engl J Med. 2008 Nov 27;359(22):2313-23
pubmed: 19038878
Cell Metab. 2017 Feb 7;25(2):345-357
pubmed: 28111214
Oncol Lett. 2017 Dec;14(6):8014-8020
pubmed: 29344244
Nat Genet. 2011 Jul 31;43(9):869-74
pubmed: 21804546
Annu Rev Immunol. 2012;30:429-57
pubmed: 22224772
Nat Immunol. 2012 Nov;13(11):1092-100
pubmed: 23001146
PLoS Genet. 2012;8(3):e1002573
pubmed: 22438825
Nat Genet. 2015 Dec;47(12):1475-81
pubmed: 26482881
Nat Immunol. 2017 Mar;18(3):303-312
pubmed: 28114292
Nat Rev Immunol. 2015 Mar;15(3):137-48
pubmed: 25656706
Cancer Discov. 2020 Sep;10(9):1352-1373
pubmed: 32571778
Mol Cell. 2016 Jun 16;62(6):890-902
pubmed: 27264869
Cell Res. 2015 Apr;25(4):429-44
pubmed: 25793315
Nature. 2017 Apr 19;544(7650):372-376
pubmed: 28425994
J Clin Oncol. 2006 Nov 1;24(31):5052-9
pubmed: 17033038
Nucleic Acids Res. 1997 Mar 15;25(6):1317-8
pubmed: 9092650
Nature. 1989 Dec 21-28;342(6252):929-31
pubmed: 2594086
Nat Rev Cancer. 2016 Oct;16(10):650-62
pubmed: 27634448
J Immunol. 2014 Apr 15;192(8):3626-36
pubmed: 24616478
Biochem J. 2012 Nov 15;448(1):165-9
pubmed: 22994860
J Biol Chem. 2004 Jan 30;279(5):3573-7
pubmed: 14645240
Sci Immunol. 2021 Feb 12;6(56):
pubmed: 33579751
Nature. 2011 Aug 18;476(7360):346-50
pubmed: 21760589
Cell Rep. 2014 May 22;7(4):1248-58
pubmed: 24813884
Blood. 2011 Oct 20;118(16):4313-20
pubmed: 21816833
Cell Rep. 2015 Oct 6;13(1):122-131
pubmed: 26411688
Lab Invest. 2018 Jul;98(7):844-855
pubmed: 29849125